obesity drug news today glp-1 september 2025 2024 was a record year for trials and is already poised to take over New weight-loss drugs surge in

Problems may arise from flaws in the drugs design, manufacturing defects, or inadequate warnings about potential side effects

MDA, malondialdehyde

More GLP-1 was needed to achieve the same biological effect, indicating the participants were GLP-1-resistant

Plaintiffs in the litigation report experiencing these specific digestive system complications: Gastroparesis (stomach paralysis): The most common injury alleged in lawsuits, this condition involves partial or complete paralysis of stomach muscles that prevents proper digestion and can persist even after discontinuing medication Ileus (intestinal blockage): Added to FDA warning labels in September 2023 after post-marketing reports, this condition stops intestinal movement and can lead to life-threatening complications including infection and tissue death Intestinal obstruction and pseudo-obstruction: Physical or functional blockages requiring emergency hospitalization and often surgical intervention to prevent bowel perforation Chronic severe symptoms: Persistent vomiting, uncontrollable nausea, dangerous dehydration requiring IV fluids, and electrolyte imbalances necessitating repeated emergency department visits The FDAs decision to update warning labels demonstrates growing concern about these complications